Syntec Optics (OPTX) investor relations material

Executive summary

• Net sales rose 26% year-over-year to $8.3 million for Q2 2026, achieving an all-time high, with growth across all four served industries, especially defense, space, and communications; six-month sales increased to $14.8 million from $13.6 million, despite a temporary dip in medical segment sales in Q1 due to a shipping hold that was resolved in Q2.

• Gross profit for Q2 2026 increased 34% to $2.1 million, with margin expansion to 26% from 24% year-over-year and 15% in Q1 2026.

• Net income turned positive at $0.3 million compared to a $0.3 million loss in Q2 2025; six-month period ended with a net loss of $0.6 million, primarily due to a weak first quarter.

• The company completed a public equity offering in Q2 2026, raising $21.4 million net, used to pay down $6.8 million in debt and close out its line of credit, significantly improving liquidity and strengthening the balance sheet.

• Inclusion in the Russell 3000® Index in Q2 2026 is expected to enhance visibility and trading liquidity.

Financial highlights

• Q2 2026 net sales: $8.3 million (up from $6.6 million in Q2 2025); six-month net sales: $14.8 million (up from $13.6 million in 2025); communications up 74%, defense up 36%, consumer up 23%.

• Q2 2026 gross profit: $2.1 million (up from $1.6 million); gross margin improved to 26% from 24% year-over-year and 15% in Q1 2026.

• Q2 2026 net income: $0.3 million (vs. $0.3 million loss in Q2 2025); six-month net loss: $0.6 million (vs. near break-even in 2025).

• Adjusted EBITDA for Q2 2026: $0.8 million (vs. $0.7 million in Q2 2025); six-month adjusted EBITDA: $0.7 million (vs. $2.1 million in 2025).

• Cash at June 30, 2026: $14.0 million (up from $0.3 million at June 30, 2025); total liabilities reduced by 43% to $8.4 million.

Outlook and guidance

• Management expects cash from operations and recent equity proceeds to fund operations and obligations for at least the next twelve months.

• Q3 2026 revenue expected between $8.3M and $9.0M, driven by biomedical, AI-enabled AR/VR, and prototype engineering; Q4 2026 revenue expected between $8.75M and $9.25M, supported by satellite optics, optical interconnects, and fusion-energy systems.

• Management targets gross margin of 35–40% and EBITDA margin of 18–20% as revenue scales.

• Strategic focus remains on expanding in defense, medical, consumer, and communications markets, with plans for bolt-on acquisitions and further automation.